We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

32 hedge funds and large institutions have $97.1M invested in ProQR Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 37 → 32 (-5)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

40% less capital invested

Capital invested by funds: $162M → $97.1M (-$65.2M)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
32
Holders Change
-5
Holders Change %
-13.51%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
10
Reduced
12
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$4.95M
2
SFM
Sphera Funds Management
Israel
+$1.73M
3
AGA
Altrinsic Global Advisors
Connecticut
+$1.15M
4
Millennium Management
Millennium Management
New York
+$842K
5
Jennison Associates
Jennison Associates
New York
+$380K

Top Sellers

Rank Fund Capital Flow
1
CCP
Clough Capital Partners
Massachusetts
-$3.15M
2
DM
Deerfield Management
New York
-$3.05M
3
CCM
Century Capital Management
Massachusetts
-$1.89M
4
RG
Redmile Group
California
-$1.19M
5
Marshall Wace
Marshall Wace
United Kingdom
-$945K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$19.7M +$4.95M +430,100 +23%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$19.6M – – –
Jennison Associates
3
Jennison Associates
New York
$8.7M +$380K +33,019 +3%
BBA
4
Baker Bros. Advisors
New York
$8.58M – – –
Millennium Management
5
Millennium Management
New York
$7.59M +$842K +73,251 +9%
JHIU
6
Janus Henderson Investors US
Colorado
$6.68M -$28.5K -2,475 -0.3%
Viking Global Investors
7
Viking Global Investors
Connecticut
$5.05M +$57.9K +5,036 +0.9%
RG
8
Redmile Group
California
$4.84M -$1.19M -103,623 -16%
ClearBridge Investments
9
ClearBridge Investments
New York
$4.33M +$5.26K +457 +0.1%
HCMT
10
Highland Capital Management (Texas)
Texas
$3.02M -$547K -47,600 -12%
Franklin Resources
11
Franklin Resources
California
$2.69M – – –
AGA
12
Altrinsic Global Advisors
Connecticut
$1.78M +$1.15M +100,000 +95%
SFM
13
Sphera Funds Management
Israel
$1.3M +$1.73M +150,000 New
Principal Financial Group
14
Principal Financial Group
Iowa
$680K -$57K -4,956 -6%
Asset Management One
15
Asset Management One
Japan
$422K -$24.2K -2,102 -4%
SM
16
Sabby Management
Florida
$346K +$206K +17,921 +82%
PC
17
Polar Capital
United Kingdom
$260K -$57.5K -5,000 -14%
ARTA
18
A.R.T. Advisors
New York
$244K +$159K +13,841 +96%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$220K -$63.8K -5,545 -18%
SIM
20
Spark Investment Management
New York
$190K +$252K +21,900 New
TAM
21
Tocqueville Asset Management
New York
$187K +$247K +21,500 New
CLM
22
ClearBridge LLC (Maryland)
Maryland
$157K – – –
Deutsche Bank
23
Deutsche Bank
Germany
$132K +$155K +13,436 +707%
Citadel Advisors
24
Citadel Advisors
Florida
$103K -$19.3K -1,676 -12%
M&T Bank
25
M&T Bank
New York
$98K +$130K +11,300 New
1
2

PRQR Hedge Fund Activity: Q4 2015 in Review

32 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2015, worth a combined $97.1M — down 40% from $162M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PRQR and 4 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 10 added.

The largest buyer was OrbiMed, adding an estimated $4.95M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $3.15M sold.

  • 32 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2015, down from 37 in Q3 2015.
  • Funds reported $97.1M of ProQR Therapeutics stock for Q4 2015, down 40% quarter-over-quarter.
  • 4 funds opened new ProQR Therapeutics positions in Q4 2015 and 9 closed out, a net change of -5 holders.
  • The largest ProQR Therapeutics buyer in Q4 2015 was OrbiMed, an estimated $4.95M added.
  • The largest ProQR Therapeutics seller in Q4 2015 was Clough Capital Partners, an estimated $3.15M sold.

Based on aggregated 13F filings for Q4 2015.